Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Blood blood.2024026388.

https://doi.org/10.1182/blood.2024026388

Published: 2024

Includes: Supplemental data

Journal Articles

TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2 V617F Mutant Mice

Maayan Levy, Huihui Li, Andrew Dunbar, Zixing Huang, Young Park, Min Lu, Pinanong Na Phattalung, Marina Planoutene, Carla Casu, Stefano Rivella, Shuling Guo, Ross L Levine, Ronald Hoffman, Yelena Ginzburg

Blood (2024) 144 (Supplement 1): 8.

https://doi.org/10.1182/blood-2024-203806

Published: 2024

Journal Articles

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, C. Cameron Yin, Christopher D. Pacheco, Christopher P. Ly, Enes Dasdemir, Evan N. Cohen, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Hagop M. Kantarjian, Zeev Estrov, Patrick K. Reville, Andrew Dunbar, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2024-211966

Published: 2024

Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Blood (2022) 140 (Supplement 1): 2016–2019.

https://doi.org/10.1182/blood-2022-166850

Published: 2022

Journal Articles

The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Shivam Rai, Jan Stetka, MARC Usart, Hui Hao-Shen, Young Park, Remie Houston, Anthony R. Martinez Benitez, Matthew Wereski, Emily Guzzardi, Sonali Persaud, Hailey Ramzan, Alan Futran, Charley Xu, Jeremy Greenwood, Sayan Mondal, Craig Masse, Ross L. Levine, Radek C. Skoda, Andrew Dunbar

Blood (2022) 140 (Supplement 1): 6722–6723.

https://doi.org/10.1182/blood-2022-162621

Published: 2022

Journal Articles

Jak2 V617F Reversible Activation Shows an Essential Requirement for Jak2 V617F in Myeloproliferative Neoplasms (MPNs)

Blood (2022) 140 (Supplement 1): 803–804.

https://doi.org/10.1182/blood-2022-164827

Published: 2022

Journal Articles

Germline Runx1 Mutations Induce Inflammation in Hematopoietic Stem and Progenitor Cells and Predispose to Hematologic Malignancies

Mohd Hafiz Ahmad, Mahesh Hegde, Waihay J. Wong, Andrew Dunbar, Anneliese Carrascoso, Lisa J Garrett, Nayara K Ferreira, Haibo Liu, Rui Li, Benjamin L. Ebert, Ross L. Levine, Julie Zhu, Scot A. Wolfe, Paul P Lui, Lucio H. Castilla

Blood (2021) 138 (Supplement 1): 2201.

https://doi.org/10.1182/blood-2021-153433

Published: 2021

Journal Articles

“Interferon” with MPN hematopoietic stem cells

Andrew Dunbar, Ross L. Levine

Blood (2021) 137 (16): 2129–2130.

https://doi.org/10.1182/blood.2021011273

Published: 2021

Journal Articles

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Blood (2021) 137 (15): 2103–2113.

https://doi.org/10.1182/blood.2020007488

Published: 2021

Includes: Supplemental data

Journal Articles

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-137552

Published: 2020

Journal Articles

Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Andrew Dunbar, MD, Min Lu, PhDMD, Mirko Farina, MD, Young Park, BS, Julie Yang, PhD, Dongjoo Kim, PhD, Abdul Karzai, BS, Mohamed E Salama, MD, Jenna Snyder, BS, Aishwarya Krishnan, BS, Richard P. Koche, PhD, Rong Fan, PhD, Ross L. Levine, MD, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-138843

Published: 2020

Journal Articles

Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism

Simon Mantha, MDMPH, Andrew Dunbar, MD, Kelly L. Bolton, MD PhD, Sean Devlin, PhD, Dmitriy Gorenshteyn, PhD, Mark Donoghue, PhD, Maria E. Arcila, MD, Gerald A. Soff, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-138579

Published: 2020

Journal Articles

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Andrew Dunbar, MD, Kelly Bolton, MD PhD, Sean M. Devlin, PhD, Francisco Sanchez-Vega, PhD, Jianjiong Gao, PhD, Jodi V. Mones, MD, Jonathan M. Wills, BA, Daniel Kelly, MS, Mirko Farina, MD, Sirish Kishore, MD, Krishna Juluru, MD, Neil Iyengar, MD, David M. Hyman, MD, Ahmet Zehir, PhD, Wungki Park, MD, Alok A Khorana, MD, Gerald A. Soff, MD, Simon Mantha, MDMPH

Blood (2019) 134 (Supplement_1): 633.

https://doi.org/10.1182/blood-2019-124242

Published: 2019

Journal Articles

Aberrant Responsiveness of Erythropoiesis to Iron Deficiency in Polycythemia Vera

Maria Feola, PhD, Daniel Moskop, Nada Terra, Young C. Park, Andrew Dunbar, MD, Ross L. Levine, MD, Ronald Hoffman, MD, Yelena Ginzburg, MD

Blood (2019) 134 (Supplement_1): 429.

https://doi.org/10.1182/blood-2019-131095

Published: 2019

Journal Articles

Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF)

Mirko Farina, MD, Simona Bernardi, PhD, Nicola Polverelli, Camilla Zanaglio, PhD, Michele Malagola, MD, Federica Re, Federica Cattina, MD PhD, Mariella D'Adda, MD, Giuseppe Rossi, Tatiana Zollner, MD, Andrew Dunbar, MD, Ross L. Levine, MD, Domenico Russo, MD

Blood (2019) 134 (Supplement_1): 1684.

https://doi.org/10.1182/blood-2019-127451

Published: 2019

Journal Articles

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

Andrew Dunbar, MD, Heidi E. Kosiorek, MS, Aishwarya Krishnan, Erin McGovern, BA, Young Park, BS, Minal A Patel, MPH, Rona Singer Weinberg, PhD, Abdulraheem Yacoub, MD, Amylou C. Dueck, PhD, John Mascarenhas, MD, Ross L. Levine, MD, Ronald Hoffman, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 1661.

https://doi.org/10.1182/blood-2019-129571

Published: 2019

Journal Articles

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Brian J Ball, Meier Hsu, MS, Sean M. Devlin, PhD, Christopher Famulare, MS, Sheng F Cai, MDPhD, Andrew Dunbar, MD, Zachary D. Epstein-Peterson, MD, Kamal Menghrajani, MD, Jacob L Glass, MDPhD, Justin Taylor, MD, Aaron D Viny, MDMS, Aaron D Goldberg, MDPhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 18.

https://doi.org/10.1182/blood-2019-125319

Published: 2019

Journal Articles

Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 1523.

https://doi.org/10.1182/blood-2018-99-112591

Published: 2018

Journal Articles

Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 292.

https://doi.org/10.1182/blood-2018-99-112938

Published: 2018

Journal Articles

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

Ying Jiang, Andrew Dunbar, Lukasz P. Gondek, Sanjay Mohan, Manjot Rataul, Christine O'Keefe, Mikkael Sekeres, Yogen Saunthararajah, Jaroslaw P. Maciejewski

Blood (2009) 113 (6): 1315–1325.

https://doi.org/10.1182/blood-2008-06-163246

Published: 2009

NARROW

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2 V617F Mutant Mice

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Jak2 V617F Reversible Activation Shows an Essential Requirement for Jak2 V617F in Myeloproliferative Neoplasms (MPNs)

Germline Runx1 Mutations Induce Inflammation in Hematopoietic Stem and Progenitor Cells and Predispose to Hematologic Malignancies

“Interferon” with MPN hematopoietic stem cells

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Aberrant Responsiveness of Erythropoiesis to Iron Deficiency in Polycythemia Vera

Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF)

Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia

Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML)

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only